RO110679B1 - Antibacterial and against fungi action product preparation process - Google Patents
Antibacterial and against fungi action product preparation process Download PDFInfo
- Publication number
- RO110679B1 RO110679B1 RO9500814A RO9500814A RO110679B1 RO 110679 B1 RO110679 B1 RO 110679B1 RO 9500814 A RO9500814 A RO 9500814A RO 9500814 A RO9500814 A RO 9500814A RO 110679 B1 RO110679 B1 RO 110679B1
- Authority
- RO
- Romania
- Prior art keywords
- ethanol
- antibacterial
- preparation process
- parts
- hydroxyquinoline
- Prior art date
Links
- 230000000844 anti-bacterial effect Effects 0.000 title claims description 5
- 241000233866 Fungi Species 0.000 title 1
- 238000002360 preparation method Methods 0.000 title 1
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims abstract description 22
- 238000000034 method Methods 0.000 claims abstract description 7
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims abstract description 7
- 239000005725 8-Hydroxyquinoline Substances 0.000 claims abstract description 6
- 229960003540 oxyquinoline Drugs 0.000 claims abstract description 6
- MCJGNVYPOGVAJF-UHFFFAOYSA-N quinolin-8-ol Chemical compound C1=CN=C2C(O)=CC=CC2=C1 MCJGNVYPOGVAJF-UHFFFAOYSA-N 0.000 claims abstract description 6
- 238000004821 distillation Methods 0.000 claims abstract description 4
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 8
- 230000000843 anti-fungal effect Effects 0.000 claims description 4
- 241001278097 Salix alba Species 0.000 claims description 3
- 238000002803 maceration Methods 0.000 claims description 2
- 238000001035 drying Methods 0.000 claims 1
- 238000010992 reflux Methods 0.000 claims 1
- 241000124033 Salix Species 0.000 abstract description 3
- ZZUFCTLCJUWOSV-UHFFFAOYSA-N furosemide Chemical compound C1=C(Cl)C(S(=O)(=O)N)=CC(C(O)=O)=C1NCC1=CC=CO1 ZZUFCTLCJUWOSV-UHFFFAOYSA-N 0.000 abstract 1
- 239000000047 product Substances 0.000 description 5
- 239000000203 mixture Substances 0.000 description 3
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 241000222122 Candida albicans Species 0.000 description 2
- 241000196324 Embryophyta Species 0.000 description 2
- 229940121375 antifungal agent Drugs 0.000 description 2
- 230000005764 inhibitory process Effects 0.000 description 2
- 230000000813 microbial effect Effects 0.000 description 2
- 239000000843 powder Substances 0.000 description 2
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonium chloride Substances [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 description 1
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 1
- 241000894006 Bacteria Species 0.000 description 1
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical compound [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 description 1
- 206010007134 Candida infections Diseases 0.000 description 1
- VEXZGXHMUGYJMC-UHFFFAOYSA-M Chloride anion Chemical compound [Cl-] VEXZGXHMUGYJMC-UHFFFAOYSA-M 0.000 description 1
- 241000588914 Enterobacter Species 0.000 description 1
- 235000013757 Juglans Nutrition 0.000 description 1
- 241000758789 Juglans Species 0.000 description 1
- 241000588747 Klebsiella pneumoniae Species 0.000 description 1
- 208000031888 Mycoses Diseases 0.000 description 1
- 241000218982 Populus nigra Species 0.000 description 1
- 241000588767 Proteus vulgaris Species 0.000 description 1
- 241000607142 Salmonella Species 0.000 description 1
- 241000191940 Staphylococcus Species 0.000 description 1
- 208000002847 Surgical Wound Diseases 0.000 description 1
- 241001442052 Symphytum Species 0.000 description 1
- 230000001476 alcoholic effect Effects 0.000 description 1
- 235000011114 ammonium hydroxide Nutrition 0.000 description 1
- 230000003266 anti-allergic effect Effects 0.000 description 1
- 230000003110 anti-inflammatory effect Effects 0.000 description 1
- 230000000890 antigenic effect Effects 0.000 description 1
- 239000001110 calcium chloride Substances 0.000 description 1
- 229910001628 calcium chloride Inorganic materials 0.000 description 1
- 229940095731 candida albicans Drugs 0.000 description 1
- 201000003984 candidiasis Diseases 0.000 description 1
- 230000001143 conditioned effect Effects 0.000 description 1
- 239000012153 distilled water Substances 0.000 description 1
- 239000003814 drug Substances 0.000 description 1
- 238000000921 elemental analysis Methods 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 230000002879 macerating effect Effects 0.000 description 1
- 229940126601 medicinal product Drugs 0.000 description 1
- WSFSSNUMVMOOMR-NJFSPNSNSA-N methanone Chemical compound O=[14CH2] WSFSSNUMVMOOMR-NJFSPNSNSA-N 0.000 description 1
- 229910052757 nitrogen Inorganic materials 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 244000052769 pathogen Species 0.000 description 1
- 230000001717 pathogenic effect Effects 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 239000002244 precipitate Substances 0.000 description 1
- 229940007042 proteus vulgaris Drugs 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
Landscapes
- Medicines Containing Plant Substances (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
Procedeul conform invenției constă în aceea că se macerează o parte Cortex Salix alba, cu 9 părți etanol 80*, la temperatura camerei și timp de 30 de zile, după care extractul obținut se refluxează cu HC1 37 % și etanol 95’, în raport de 1:1:1 și cu adaos de 0,145 părți 8-hidroxichinoliriâ, după care produsul obținut se izolează, prin distilarea excesului de alcool-apă, se neutralizează cu soluție NH3 25%, se spală și se usucă.The process according to the invention consists in that a part of the Salix Cortex is machined, with 9 parts of ethanol 80%, at room temperature and for 30 days, after which the extract obtained is is refluxed with 37% HCl and 95% ethanol, in a ratio of 1: 1: 1 and with the addition of 0.145 parts of 8-hydroxyquinoline, after which the product obtained is isolated by distillation of excess alcohol-water is neutralized with 25% NH3 solution, washed and dried.
Description
Prezenta invenție se referă la un procedeu de obținere a unui produs cu acțiune antibacteriană și antifungică, utilizat în medicina umană, la tratarea afecțiunilor dermatologice.The present invention relates to a process for obtaining a product with antibacterial and antifungal action, used in human medicine, for the treatment of dermatological conditions.
Sunt cunoscute procedee de obținere a produselor medicamentoase, cu acțiune antibacteriană și antigungică, folosind plante medicinale, cum ar fi, de exemplu, procedeul ce constă în aceea că, un amestec de plante, ce conține Radix Symphytum, Flores Calendulae, Folium Juglans, Turioni Populus nigra și Flores Arnica se macerează timp de 10...15 zile, la temperatura camerei în etanol 80° (raport 2:26), după care se refluxează cu formaldehidă, acid clorhidric și 8hidroxichinolină și produsul obținut se izolează prin distilarea excesului de alcool-apă, după care se usucă.Processes for obtaining medicinal products, with antibacterial and antigenic action, are known, using medicinal plants, such as, for example, the process consisting of a mixture of plants containing Radix Symphytum, Flores Calendulae, Folium Juglans, Turioni Populus nigra and Flores Arnica are macerated for 10 ... 15 days, at room temperature in ethanol 80 ° (2:26 ratio), then refluxed with formaldehyde, hydrochloric acid and 8hydroxyquinoline and the product obtained is isolated by distillation of excess alcohol-water, then dried.
Procedeul conform invenției constă în aceea că se macerează 1 parte Cortex Salix alba cu 9 părți etanol 80°, la temperatura camerei și timp de 30 de zile, după care extractul obținut se refluxează cu HCI 37% și etanol 95° în raport de 1; 1:1 și cu adaos de 0,145 părți 8hidroxichinolină, după care produsul obținut se izolează, prin distilarea excesului de alcool-apă, se neutralizează cu soluție NH3 25%, se spală și se usucă.The process according to the invention consists of macerating 1 part Cortex Salix alba with 9 parts 80 ° ethanol, at room temperature and for 30 days, after which the extract obtained is refluxed with 37% HCl and 95 ° ethanol in a ratio of 1; 1: 1 and with the addition of 0.145 parts 8-hydroxyquinoline, after which the obtained product is isolated, by distillation of excess alcohol-water, neutralized with 25% NH 3 solution, washed and dried.
Avantajul acestui procedeu constă în aceea că, produsul obținut are o bună activitate farmacologică, prin acțiunea sinergetică a principiilor active, în ceea ce privește acțiunea microbiană, antifungică, antiinflamatoare, epitelizantă și antialgică.The advantage of this process is that the product obtained has a good pharmacological activity, through the synergistic action of the active principles, regarding the microbial, antifungal, anti-inflammatory, epithelializing and antiallergic action.
Se dă, în continuare, un exemplu de realizare a invenției. Se macerează timp de 30 de zile, la temperatura camerei și într-un balon de 2 I, o cantitate de 100 g coajă de Salix alba (salcie] în 900 g de etanol 80%. După peroada de macerare, se refluxează amestecul, timp de 8...10 h și apoi se filtrează sub vid. Din extractul obținut, se realizează un amestec din 100 ml de extract alcoolic de coajă de salcie, obținut cu 14,5 g (0,2 moli) de 8hidroxichinolină, care a fost solubilizată în 100 ml etanol 95% și 100 ml de acid clorhidric 37% și se refluxează pe baia de apă, timp deThe following is an example of an embodiment of the invention. It is macerated for 30 days, at room temperature and in a 2 L flask, 100 g of Salix alba (willow) in 900 g of 80% ethanol. After maceration, the mixture is refluxed for a while of 8 ... 10 h and then filtered under vacuum. From the extract obtained, a mixture of 100 ml of alcoholic willow bark extract, obtained with 14.5 g (0.2 moles) of 8 hydroxyquinoline, was obtained. was solubilized in 100 ml of 95% ethanol and 100 ml of 37% hydrochloric acid and refluxed on the water bath for
5.. .10h.5 .. .10h.
După îndepărtarea excesului de alcool și apă, reziduul obținut se tratează cu 150 ml de amoniac soluție 25%. Precipitatul obținut se filtrează sub vid și se spală cu apa distilată, până la îndepărtarea ionului de clor. Se usucă la aer, apoi într-un exicator pe clorură de calciu. Se obține o pulbere microcristalină, de culoare maron. Analiza elementară a furnizat un procent de 6,60...6,26% azot.After removal of excess alcohol and water, the residue obtained is treated with 150 ml of ammonia solution 25%. The precipitate obtained is filtered under vacuum and washed with distilled water, until the chlorine ion is removed. Dry in air, then in a calcium chloride dryer. A brown, microcrystalline powder is obtained. Elemental analysis provided a percentage of 6.60 ... 6.26% nitrogen.
Se obține cu un randament deIt is obtained with a yield of
80.. .90%.80 .. .90%.
Activitatea antibacteriană s-a efectuat in vitro calitativ, pe următoarele tulpini de germeni: Stafilococ patogen, Bacii Colii, Klebsiella pneumoniae, Proteus vulgaris, Salmonella tip B și Enterobacter, prezentând o zonă de inhibiție de 25...40 mm.Antibacterial activity was performed in vitro qualitatively, on the following germ strains: Staphylococcus pathogen, Bacteria Colii, Klebsiella pneumoniae, Proteus vulgaris, Salmonella type B and Enterobacter, having an inhibition zone of 25 ... 40 mm.
De asemenea, s-a testat și din punct de vedere antifungic, pe Candida albicans, prezentând zone de inhibiție de 35...60 mm. Produsul obținut se poate condiționa, atât sub formă de pudră, cât și sub formă de unguent, cu aplicare la sterilizarea plăgilor chirurgicale infectate, post operatoriu, în tratamentul afecțiunilor dermatologice, microbiene și fungice, în ORL, în vulvuvaginite candidozice, arsuri de gradul II, etc.Also, from the antifungal point of view, Candida albicans was tested, showing inhibition zones of 35 ... 60 mm. The obtained product can be conditioned, both in powder form and in the form of ointment, with application to sterilizing the infected surgical wounds, post-operatively, in the treatment of dermatological, microbial and fungal diseases, in ENT, in candidiasis vulvuvaginite, grade II burns. , etc.
Claims (1)
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO9500814A RO110679B1 (en) | 1995-04-27 | 1995-04-27 | Antibacterial and against fungi action product preparation process |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| RO9500814A RO110679B1 (en) | 1995-04-27 | 1995-04-27 | Antibacterial and against fungi action product preparation process |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RO110679B1 true RO110679B1 (en) | 1996-03-29 |
Family
ID=20102111
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RO9500814A RO110679B1 (en) | 1995-04-27 | 1995-04-27 | Antibacterial and against fungi action product preparation process |
Country Status (1)
| Country | Link |
|---|---|
| RO (1) | RO110679B1 (en) |
Cited By (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130295204A1 (en) * | 2010-12-09 | 2013-11-07 | Y&B Mother's Choice Ltd. | Formulations comprising saponins and uses thereof |
| US10064881B2 (en) * | 2010-12-09 | 2018-09-04 | Y&B Mother's Choice Ltd. | Natural formulations |
| US10117827B2 (en) | 2013-12-08 | 2018-11-06 | Y&B Mother's Choice Ltd. | Preparations for suppressing or attenuating ocular irritancy |
| US10434058B2 (en) | 2010-12-09 | 2019-10-08 | Y&B Mother's Choice Ltd. | Natural formulations |
-
1995
- 1995-04-27 RO RO9500814A patent/RO110679B1/en unknown
Cited By (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20130295204A1 (en) * | 2010-12-09 | 2013-11-07 | Y&B Mother's Choice Ltd. | Formulations comprising saponins and uses thereof |
| US9474283B2 (en) * | 2010-12-09 | 2016-10-25 | Y&B Mother's Choice Ltd. | Formulations comprising saponins and uses thereof |
| US10064881B2 (en) * | 2010-12-09 | 2018-09-04 | Y&B Mother's Choice Ltd. | Natural formulations |
| US10434058B2 (en) | 2010-12-09 | 2019-10-08 | Y&B Mother's Choice Ltd. | Natural formulations |
| US10117827B2 (en) | 2013-12-08 | 2018-11-06 | Y&B Mother's Choice Ltd. | Preparations for suppressing or attenuating ocular irritancy |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Ratheesh et al. | Anti-inflammatory activity of Ruta graveolens Linn on carrageenan induced paw edema in wistar male rats | |
| RU2361601C2 (en) | Composition for treatment of atopic dermatitises, allergic conditions of skin and blackhead | |
| KR101870979B1 (en) | Formulations for the treatment of disorders of the upper respiratory tract | |
| US20110245337A1 (en) | Method for enhancing the dna repair process, treating disorders associated with the dna repair process, enhancing antitumor response and treating disorders associated with anti-tumor response in mammals by administering purified quinic acid and/or carboxy alkyl ester | |
| CN104840490A (en) | Plant extract hydrolysates and antibacterial product containing the same | |
| US20100120903A1 (en) | Anti-inflammatory agent | |
| EP2825185B1 (en) | Novel methods and compositions for treatment of disease | |
| Gbedema et al. | Wound healing properties and kill kinetics of Clerodendron splendens G. Don, a Ghanaian wound healing plant | |
| Lawal et al. | Phytochemical and antioxidant investigations of a Clausena anisata hook, a South African medicinal plant | |
| Tripathi et al. | EVALUATION OF ANTI–INFLAMMATORY ACTIVITY OF PLANT EXTRACT OF CORDIA DICHOTOMA LEAVES ON CARRAGEENAN-INDUCED PAW EDEMA IN ALBINO WISTER RATS AND ITS PHYTOCHEMICAL ANALYSIS | |
| Nakalembe et al. | Analgesic and anti-inflammatory activity of total crude leaf extract of Phytolacca dodecandra in Wistar Albino Rats | |
| KR101333150B1 (en) | Antibacterial compositions containing plant extracts or fractions thereof under light intensity | |
| RO110679B1 (en) | Antibacterial and against fungi action product preparation process | |
| US5641481A (en) | Composition to control dermatomycoses and their pathogens, perspiration and body odor | |
| CN100399906C (en) | A fungal fruiting body extract for inducing plant disease resistance | |
| Dashti | Antiviral properties of Peganum harmala (Espand) as a medicinal plant: A literature review | |
| Reid et al. | Pharmacological and phytochemical properties of Dombeya rotundifolia | |
| Singh et al. | A review on Hibiscus rosa-sinensis, extraction and its pharmacological activity | |
| KR100672036B1 (en) | Asthma Treatments with Honey Extract | |
| Waghulde et al. | Comparative anti-inflammatory activity of aril extracts of punica granatum fruits | |
| Fatima et al. | 67. Antifungal activity of crude extracts of stem-bark of Acacia ampliceps Maslin.(Family Leguminosae) | |
| Onwuka et al. | Evaluation of the anti-inflammatory activities of solvent fractions of Commelina ascendens | |
| EP1492550B1 (en) | Willow extract | |
| Polovko | THEORETICAL JUSTIFICATION OF CHOICE OF ANTI-HERPETIC PHYTOSUBSTANCE | |
| Karam | Efficiency evaluation of alkaloids from pomegranatE (Punica granatum) peels towards some pathogenic fungi of human |